| --- | --- | --- | --- | --- | --- | |-----------------------------------------------------------------------------------------------------|-------|-------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Revolutionizing the Treatment of Infections Associated with Chronic Disease Through Phage Therapy | | | | | | | INVESTOR PRESENTATION | | | | | | | November 2024 | | | | | | | NYSE American: PHGE | | | | | | 1 SAFE HARBOR STATEMENT About this Presentation Th ...

Clinical Trials - Patient enrollment for the BX211 Phase 2 trial in Diabetic Foot Osteomyelitis (DFO) has been completed, with topline results expected in Q1 2025[2] - In the BX004 Phase 1b/2a trial, 14.3% of patients converted to sputum culture negative for Pseudomonas aeruginosa after 10 days of treatment, compared to 0% in the placebo arm[6] - The company expects to report topline results for the BX004 Phase 2b study in the first half of 2026 following resolved manufacturing delays[2] Financial Performance - BiomX reported a net income of $9.6 million for Q3 2024, compared to a net loss of $7.9 million in Q3 2023, primarily due to changes in the fair value of warrants[14] - Operating loss for the nine months ended September 30, 2024, was $27,838 million, compared to $20,076 million for the same period in 2023, indicating a 38.5% increase in losses[26] - Net loss for the three months ended September 30, 2024, was $9,642 million, compared to a net income of $7,906 million in the same period last year, marking a significant shift in performance[26] - Basic loss per share for the three months ended September 30, 2024, was $(0.31), compared to earnings of $1.30 per share in the same period last year[26] Expenses - Research and development expenses increased to $7.3 million in Q3 2024 from $5.6 million in Q3 2023, driven by preparations for the Phase 2b clinical trial of BX004 and increased expenses related to BX211[11] - General and administrative expenses rose to $3.2 million in Q3 2024 from $2.2 million in Q3 2023, attributed to the consolidation of expenses after the acquisition of Adaptive Phage Therapeutics[12] - Research and development (R&D) expenses for the three months ended September 30, 2024, were $7,279 million, up from $5,641 million in the same period last year, reflecting a 29% increase[26] Cash and Assets - Cash balance as of September 30, 2024, was $24.7 million, down from $30.7 million as of December 31, 2023, due to net cash used in operating activities[9] - BiomX estimates its cash and equivalents are sufficient to fund operations into the fourth quarter of 2025[9] - Total current assets increased to $28,316 million as of September 30, 2024, compared to $17,632 million as of December 31, 2023, representing a growth of 60.5%[24] - Total non-current assets rose to $31,664 million as of September 30, 2024, from $7,397 million as of December 31, 2023, an increase of 327%[24] - Total current liabilities decreased to $8,944 million as of September 30, 2024, from $11,176 million as of December 31, 2023, a reduction of 19.8%[25] Stock and Shareholder Information - The company conducted a 1-for-10 reverse stock split in August 2024, consolidating every ten shares into one[7] - The weighted average number of shares used in computing basic loss per share increased to 16,366,122 for the three months ended September 30, 2024, from 6,058,774 in the same period last year[26] Liabilities - The company reported a significant increase in operating lease liabilities, which rose to $8,651 million as of September 30, 2024, compared to $3,239 million as of December 31, 2023[25] - The company recorded a loss from the change in fair value of Private Placement Warrants amounting to $(20,559) million for the three months ended September 30, 2024[26]

BX211 Phase 2 for treatment of Diabetic Foot Osteomyelitis (DFO) patient enrollment completed and on track to report topline results in Q1 2025 BX004 Phase 2b study in Cystic Fibrosis (CF) is now expected to report topline results in H1 2026 following resolved manufacturing delays Company to host conference call and webcast today at 8:00AM ET NESS ZIONA, Israel, Nov. 14, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE, the “Company” or “BiomX”), a clinical-stage company advancing novel natural and ...

NESS ZIONA, Israel, Nov. 12, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) ("BiomX" or the "Company"), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that the Company will host a conference call and a live audio webcast on Thursday, November 14, 2024, at 8:00 a.m. ET, to report third quarter 2024 financial results and provide business and program updates. To participate in the conference call, please dial ...

GAITHERSBURG, Md., Oct. 15, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) ("BiomX" or the "Company"), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, announces a mandatory separation of its units, which trade under the ticker symbol "PHGE.U", each of which consists of one share of Common Stock and one warrant to purchase one-half of a share of Common Stock (the "Units"). Each warrant (a "Warrant") entitles the holder to pu ...

BiomX Inc. (PHGE) recently announced the presentation of data from its Phase 1b/2a study for BX004 — a fixed multi-phage cocktail. BX004 is used for treating cystic fibrosis (CF) patients with chronic pulmonary infections caused by Pseudomonas aeruginosa (PsA). BiomX will present this study data at the North American Cystic Fibrosis Conference in Boston. PHGE Stock's Likely Trend Following the News Shares of PHGE rose 2.8% to $1.05 yesterday following the news. To date, BX004 has been under several trials. ...

GAITHERSBURG, Md., Sept. 18, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) ("BiomX" or the "Company"), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, announces the Company will present further data from BiomX's Phase 1b/2a study of BX004 for the treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa pulmonary infections. The findings will be presented in two sessions at the North American Cystic Fibrosi ...

GAITHERSBURG, Md., Sept. 04, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) ("BiomX" or the "Company"), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, announces today that Jonathan Solomon, Chief Executive Officer, will present a corporate overview at the H.C. Wainwright 26th Annual Global Investment Conference. The conference is being held on September 9 - 11, 2024 at the Lotte New York Palace Hotel. Presentation Date: Se ...

In a release issued under the same headline yesterday by BiomX (NYSE American: PHGE), the third and fourth paragraphs have been updated to include information regarding adjustment of outstanding units following the reverse stock split GAITHERSBURG, Md., Aug. 16, 2024 (GLOBE NEWSWIRE) -- In a release issued under the same headline yesterday by BiomX (NYSE American: PHGE), the third and fourth paragraphs have been updated to include information regarding adjustment of outstanding units following the reverse s ...

BiomX Inc. (NYSE:PHGE) Q2 2024 Earnings Call Transcript August 15, 2024 8:00 AM ET Company Participants Marina Wolfson - CFO Jonathan Solomon - CEO Conference Call Participants Yale Jen - Laidlaw & Company Farhana Sakloth - Ladenburg Thalmann Operator Greetings, and welcome to BiomX Second Quarter 2024 Financial Results Conference Call. At this time, all participants are in a listen-only mode. A brief question-and-answer session will follow the formal presentation. [Operator Instructions] As a reminder, thi ...